The accusations of cocaine use and having sex with someone else's wife are the least of Marc Beer's problems. Aegerion Pharmaceuticals, the company he runs as CEO, is falling apart.
Aegerion Pharmaceuticals issued a statement Tuesday night expressing its board's support for CEO Marc Beer in the face of accusations of cocaine use and extramarital sex.
Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.
FDA concerns about the reliability of clinical data for a muscular dystrophy drug raise investor concerns about Sarepta's path toward approval.
Both CEOs deny allegations in an ugly divorce case that they snorted cocaine with a Jefferies & Co. health care investment banker.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Alcobra disclose new details about the phase III study of attention-deficit hyperactivity disorder drug candidate which contradict results announced by the company in an Oct. 6 press release.
But you're getting way ahead of the facts if you think Regulus has a game-changing hepatitis C therapy in its grasp already. There's a lot more questions to be answered.
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.
Shire isn't obligated to spend AbbVie's money, but it's no fun speculating about earned interest. Which drug companies might be takeout targets for Shire?